A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Patients With Active Cutaneous Discoid Lesions.

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Patients With Active Cutaneous Discoid Lesions.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs R 333 (Primary)
  • Indications Discoid lupus erythematosus; Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms SKINDLE
  • Sponsors Rigel Pharmaceuticals
  • Most Recent Events

    • 24 Oct 2013 Results published in a Rigel Pharmaceuticals media release.
    • 24 Oct 2013 Primary endpoint 'Clinical-response-rate (in total combined Erythema and Scaling score)' has not been met, according to a Rigel Pharmaceuticals media release.
    • 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top